Core Viewpoint - Picard Medical, Inc. has announced a definitive agreement for a private placement financing of up to $50 million in senior secured notes due 2028, along with warrants for common stock purchase [1][2]. Group 1: Financing Details - The company plans to issue an initial $15 million principal amount of notes at closing, with an option to fund an additional $35 million in one or more tranches, subject to certain conditions [2]. - The notes will be senior secured obligations of the company, indicating a priority claim on assets in case of liquidation [2]. Group 2: Use of Proceeds - The net proceeds from this financing will be utilized for working capital and general corporate purposes [2]. Group 3: Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is known for its SynCardia Total Artificial Heart, the first artificial heart approved by both the U.S. FDA and Health Canada [4]. - SynCardia's technology is the only commercially available total artificial heart for patients with end-stage heart failure, with over 2,100 implants performed across 27 countries, making it the most widely used artificial heart globally [4].